Vulval Cancer: When should I Stop Resecting? Identifying the Factors that Predict Recurrence

Abstract

Context: Vulval cancer surgery has become more conservative and it is important to understand whether resection margins alone influence recurrence rates or whether other prognostic factors should be considered when planning treatment. Aims: The aim of this study is to define factors that predict vulval cancer recurrence, enabling development of a recurrence prediction model. Settings and Design: This was a Aretrospective descriptive analysis of new vulval squamous cell carcinoma cases in a gynecological oncology center (January 1, 2007 to December 31, 2013). Subjects and Methods: Analysis of tumor characteristics and treatments. Patient outcomes were recorded, identifying recurrences, and subsequent interventions. Statistical Analysis Used: Univariable and multivariable logistic regression tools applied to determine recurrence risk factors. Results: Seventy patients underwent primary vulval surgery. Bilateral groin node dissection was performed in 26/70 (37.1%) cases and unilateral groin node dissection in 9/70 (12.9%) cases. 57/70 (82%) cases had a negative vulval resection margin, with 67% <8-mm margin. 18/70 (26%) patients underwent adjuvant treatment. Overall recurrence rate of 21/70 (30%): 14/70 locally and 7/70 at the groin. Median survival was 84.2 months and median disease-free interval was 19.1 months. Factors that were statistically significant in predicting recurrence were positive groin histology, lymphovascular space invasion (LVSI), and disease stage. Conclusions: We reported a reduction in the size of tumor-free margins at primary excision. The recurrence rate of 30% is within the previously reported range, suggesting that factors aside from resection margin (LVSI, stage, and groin node involvement) are also important in predicting recurrence. These factors should be incorporated into a prediction model when planning adjuvant treatment.

Keywords

Recurrence factors - resection margin - vulval cancer

Publication History

Received: 04 August 2017

Accepted: 18 April 2018

Article published online:
03 June 2021

• References

• 1 Cancer Research. Information Originally Obtained from Office National Statistics. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/vulval-cancer#heading-Two Available from: [Last accessed on 2017 Jul 16]
• 2 Royal College of Obstetricians and Gynaecologists/British Gynaecological Cancer Society. Guidelines for the Diagnosis and Management of Vulval Carcinoma. London, UK: Royal College of Obstetricians and Gynaecologists/British Gynaecological Cancer Society; 2014
• 3 Royal College of Pathologists. Datasets for the Histopathological Reporting of Vulval Neoplasms. 3rd ed. London, UK: Royal College of Pathologists; 2010
• 4 Yap J, O'Neill D, Nagenthiran S, Dawson CW, Luesley DM. Current insights into the aetiology, pathobiology, and management of local disease recurrence in squamous cell carcinoma of the vulva. BJOG 2017; 124: 946-54
• 5 Heaps JM, Fu YS, Montz FJ, Hacker NF, Berek JS. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol 1990; 38: 309-14
• 6 De Hullu JA, Hollema H, Lolkema S, Boezen M, Boonstra H, Burger MP. et al. Vulvar carcinoma. The price of less radical surgery. Cancer 2002; 95: 2331-8
• 7 Van der Velden J. Surgical interventions for early squamous cell carcinoma of the vulva. Cochrane Database of Systematic Reviews 2000; 2 Art. No.: CD002036.
• 8 Burke TW, Levenback C, Coleman RL, Morris M, Silva EG, Gershenson DM. et al. Surgical therapy of T1 and T2 vulvar carcinoma: Further experience with radical wide excision and selective inguinal lymphadenectomy. Gynecol Oncol 1995; 57: 215-20
• 9 DiSaia PJ, Creasman WT, Rich WM. An alternate approach to early cancer of the vulva. Am J Obstet Gynecol 1979; 133: 825-32
• 10 Woelber L, Griebel LF, Eulenburg C, Sehouli J, Jueckstock J, Hilpert F. et al. Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study. Eur J Cancer 2016; 69: 180-8
• 11 Hacker NF, Van der Velden J. Conservative management of early vulvar cancer. Cancer 1993; 71: 1673-7
• 12 Falconer AD, Hirschowitz L, Weeks J, Murdoch J. South West Gynaecology Tumour Panel. The impact of improving outcomes guidance on surgical management of vulval squamous cell cancer in Southwest England (1997-2002). BJOG 2007; 114: 391-7
• 13 Moskovic EC, Shepherd JH, Barton DP, Trott PA, Nasiri N, Thomas JM. et al. The role of high resolution ultrasound with guided cytology of groin lymph nodes in the management of squamous cell carcinoma of the vulva: A pilot study. Br J Obstet Gynaecol 1999; 106: 863-7
• 14 Piura B, Masotina A, Murdoch J, Lopes A, Morgan P, Monaghan J. et al. Recurrent squamous cell carcinoma of the vulva: A study of 73 cases. Gynecol Oncol 1993; 48: 189-95
• 15 Dardarian TS, Gray HJ, Morgan MA, Rubin SC, Randall TC. Saphenous vein sparing during inguinal lymphadenectomy to reduce morbidity in patients with vulvar carcinoma. Gynecol Oncol 2006; 101: 140-2